Dr. Jean Hoffman-Censits on the Results of a Phase II Trial Studying Atezolizumab in Bladder Cancer

January 13, 2016
Jean Hoffman-Censits, MD

Hoffman-Censits says outside of the first-line therapy of cisplatin-based chemotherapy in locally advanced unresectable bladder cancer tumors, there are currently no solutions for disease progression.

Jean Hoffman-Censits, MD, medical oncologist, director, Multidisciplinary Genitourinary Oncology Center, Thomas Jefferson University Hospital, discusses the investigational PD-L1 inhibitor atezolizumab. Hoffman-Censits says outside of the first-line cisplatin-based chemotherapy in locally advanced unresectable bladder cancer tumors, there are currently no solutions for disease progression. She says patients who experienced progression were enrolled into a recent trial testing atezolizumab's efficacy against the malignancy.